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The transcription factor p53 lies at the centre of a protein network which controls cell cycle 
progression and commitment to apoptosis [1]. p53 is inactive in proliferating cells, due largely to 
negative-regulation by the hdm2 / mdm2 oncoprotein, with which it physically associates. 
Release from this negative regulation is sufficient to activate p53 [2], and can be triggered in 
cells by multiple stimuli, through diverse pathways [3-5]. This diversity is achieved in part 
because hdm2 uses multiple mechanisms to inactivate p53: it targets p53 for ubiquitination and 
degradation by the proteosome [6-8], shuttles it out of the nucleus and into the cytoplasm [9, 10], 
prevents its interaction with transcriptional co-activators [11], and contains an intrinsic 
transcriptional repressor activity [12]. Here we show that hdm2 can also repress p53 activity 
through the recruitment of a known transcriptional co-repressor, hCtBP2 [13, 14]. This 
interaction, and consequent repression of p53-dependent transcription, is relieved under hypoxia 
or hypoxia-mimicking conditions that are known to increase levels of intracellular NADH. CtBP 
proteins can undergo an NADH-induced conformational change [15], which we show here 
results in a loss of their hdm2 binding ability. This pathway represents a novel mechanism 
whereby p53 activity can be induced by cellular stress. 
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RESULTS AND DISCUSSION 
 
Screening of a human HeLa cell cDNA expression library with recombinant hdm2 protein 
identified CtBP2 as a potential hdm2 binding partner (not shown). A GST-human CtBP2 (GST-
hCtBP2) fusion protein, but not other GST-fusion controls, was able to capture the 90 kD hdm2 
protein from a partially purified bacterial lysate (Figure 1A). Furthermore, when lysates of E. 
coli which had been induced to express human proteins (either p53 or hdm2) were subjected to 
farwestern analysis using GST-hCtBP2 as a probe, a 90 kD band was detected only in hdm2 
containing lysates (see supplementary material). These experiments demonstrate that hdm2 and 
hCtBP2 can associate specifically in vitro. Further experiments in vitro determined that the 
interaction occurs rapidly (30 min. co-incubation is sufficient for near-maximal binding under 
these assay conditions) and, once formed, is stable over a 24 hour incubation period and cannot 
be disrupted by high ionic strength (600 mM NaCl) buffer (not shown).  
 
We then sought to determine whether the hdm2:hCtBP2 interaction can be detected in vivo. 
Hdm2 and either myc epitope-tagged hCtBP2 or myc-β-galactosidase control were transiently 
over-expressed in HEK 293 cells and cell lysates subjected to immunoprecipitation with anti-
myc antibody. Hdm2 protein was co-immunoprecipitated from the myc-hCtBP2 containing 
lysates but not the myc-β-galactosidase control (see supplementary material). Similar co-
immunoprecipitation experiments were performed on non-transfected MCF-7 cell lysates using 
anti-CtBP antibody. Hdm2 co-immunoprecipitated specifically with the anti-CtBP antibody, but 
not in control precipitations (Figure 1B), demonstrating a naturally-occurring interaction 
between endogenous hdm2 and hCtBP2 proteins in vivo.  
 
hCtBP2 is a 445 a.a. protein which shares 83% sequence similarity with its homologue, hCtBP1. 
Both proteins have orthologues in the mouse, whereas xenopus and drosophila each express a 
single CtBP molecule [13, 14]. All CtBP proteins contain a highly conserved central domain 
with significant sequence similarity to a family of D-isomer specific 2-hydroxyacid 
dehydrogenases [13, 14]. This domain is located between a.a. 106-353 in hCtBP2. The N-
terminus of CtBP family members contains a protein:protein interaction domain, through which 
they are recruited to proteins containing a consensus PXDLS motif [16, 17]. We used GST ‘pull-
down’ assays to test a series of GST-hCtBP2 deletion mutants for their ability to bind hdm2 
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(Figure 1C). A mutant containing amino acids 1-110 pulled down hdm2 as effectively as the full-
length protein (lane 5), whereas 110-445 did not pull-down hdm2 (lane 3). Therefore the N-
terminal domain of hCtBP2 is both necessary and sufficient for the interaction with hdm2. A 
mutant lacking the C-terminal 86 amino acids (construct 1-359, lane 2) consistently pulled-down 
less hdm2 than the full length protein, despite the lack of any direct hdm2 binding-site in this 
region (see lane 3). This latter finding is consistent with previous reports which have indicated a 
regulatory role for the C-terminus of CtBP-proteins on N-terminal protein:protein interactions 
[18, 19]. 
 
To determine which domain of hdm2 interacts with hCtBP2, we also constructed a panel of 
hdm2 truncation mutants. Hdm2(6-306) bound the N-terminal domain of hCTBP2 (Figure 1D, 
lane 3), albeit less strongly than full length hdm2, whereas hdm2(6-210) did not bind (lane 2). 
The a.a. 210-306 section of hdm2 that these experiments identify as being required for hCtBP2 
binding primarily consists of the acidic domain, which is known to both regulate hdm2 function 
[20] and interact with proteins including p300, Rb, TBP, ARF, and MTBP [21]. The hdm2 
paralogue, hdmX [22], shares some homology with hdm2 within the acidic domain and can also 
interact with hCtBP2 in vitro (see supplementary material). Furthermore, the hCtBP2 paralogue, 
hCtBP1, is able to interact with hdm2 in GST ‘pull-down’ assays (see supplementary material). 
 
The recruitment of hCtBP1 by proteins containing a PXDLS motif is regulated by changes in 
cellular redox potential [15]. The central dehydrogenase domain of hCtBP1 contains a high 
affinity binding-site for NADH (GXGXXG, Figure 2A), occupation of which induces a 
conformational change in the hCtBP1 molecule and an increase in binding to proteins such as 
E1A and ZEB. A mutation in hCtBP1 in the GXGXXG motif (G183A) abolishes NADH-
responsiveness [15]. We noted that this site in hCtBP2 is conserved (a.a. 187-192) and asked 
whether NADH could regulate the hdm2:hCtBP2 interaction. Concentrations of NADH (0.01 to 
1 mM) known to promote the interaction of hCtBP1 with PXDLS motif-proteins, inhibited 
binding of full length GST-hCtBP2 to hdm2 (Figure 2B, top panel). This inhibition did not occur 
when either GST-hCtBP2(1-110), lacking the dehydrogenase domain, or hCtBP2(G189A), 
containing a mutation in the NADH-binding site, were used in the assays (Figure 2B, lower 
panels). Therefore, in contrast to interactions with PXDLS-motif proteins, the conformational 
changes induced by NADH-binding to the CtBP dehydrogenase domain result in a reduced 
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affinity of hCtBP2 for hdm2. Exposure of cells in culture to CoCl2 can be used as a model for the 
induction of a hypoxia-like stress-response. Zhang et al [15] have shown that CoCl2 treatment 
(200µM) induces an increase in the cellular NADH/NAD+ ratio sufficient to promote binding of 
CtBP proteins to PXDLS motif-proteins in the cell. As shown in Figure 2C, 200 µM CoCl2 
reduced the formation of hdm2:hCtBP2 complexes in MCF-7 cells. Hypoxia, which has a greater 
effect on the cellular NADH/NAD+ ratio than CoCl2 [15], was more effective than CoCl2 in 
reducing the hdm2:hCtBP2 interaction (Figure 2C). These data demonstrate, therefore, that the 
NADH-induced regulation of the hdm2:hCtBP2 interaction also occurs in vivo. 
 
To determine the functional consequences of the hdm2:hCtBP2 interaction, we examined 
whether over-expression of either molecule would modify the function of the other. Hdm2 
regulates p53 levels in cells by directing the nuclear export of p53 and targeting it to the 
ubiquitin-proteasome degradation pathway [6-10]. We therefore tested whether hdm2 could 
regulate hCtBP2 protein levels. HEK 293 cells were transiently transfected with vectors 
encoding myc-tagged hCtBP2, and increasing amounts of hdm2. Hdm2 did not decrease hCtBP2 
expression levels in this assay (see supplementary material) providing evidence that hdm2 does 
not target hCtBP2 for proteosome-mediated degradradation, nor did it have an effect on the 
intracellular localisation of hCtBP2 in HEK 293 cells (data not shown). The best documented 
function of CtBP proteins is as short-range transcriptional co-repressors [13, 14]. Thus, CtBP 
proteins are recruited to promoters by sequence specific DNA-binding transcription factors, 
either through a direct physical interaction, or indirectly through bridging proteins. We therefore 
tested whether the formation of an hdm2:hCtBP2 complex could modify the ability of hdm2 to 
repress p53-dependent transcription. For this experiment we used three different p53 responsive 
luciferase reporters: bax-Luc, hdm2-Luc03, and p21-Luc containing promoter regions from bax, 
hdm2 and p21WAF-1 respectively. In the presence of hdm2, hCtBP2 reproducibly repressed p53-
dependent transcription from the bax-Luc and hdm2-Luc reporters, but was without effect on 
p21-Luc (Figure 3A). 
 
To confirm that the inhibition of p53-dependent transcription by hCtBP2 is dependent on a direct 
interaction between hdm2 and hCtBP2, cells were treated with CoCl2 to disrupt the 
hdm2:hCtBP2 interaction. Following CoCl2 exposure, hCtBP2 was no longer able to enhance 
hdm2-mediated repression of p53-dependent transcription (Figure 3B), this was not due to an 
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effect on p53 protein levels in these cells (data not shown). This effect of CoCl2 was due to its 
specific effect on regulating intracellular NADH levels, since repression by the hCtBP2(G189A) 
mutant was unaffected by CoCl2 (Figure 3C). In addition, we transfected cells with an hdm2(1-
210) mutant which can bind p53, is localised in the nucleus, and can inhibit p53 activity, but 
cannot bind hCtBP2. In the presence of hdm2(1-210), hCtBP2 did not repress p53-dependent 
transcription. (Figure 3D), confirming that an interaction between hdm2 and hCtBP2 is required 
for hCtBP2 to be able to repress p53-dependent transcription.  
 
One model that could account for our observation is that an hdm2:hCtBP2 complex directly 
interacts with p53 to bring about repression of p53 transactivating ability. The binding sites for 
p53 and hCtBP2 on hdm2 are located in distinct domains, suggesting that a trimeric complex of 
p53:hdm2:hCtBP2 could form. Figure 4A demonstrates that, when combinations of hdm2, GST-
hCtBP2(1-110), and p53 are co-incubated in vitro, p53 co-precipitates with GST-hCtBP2 (1-110) 
only in the presence of hdm2. Therefore hdm2 is able to recruit hCtBP2 to p53. In this model 
(Figure 4B) the role of hdm2 as a bridging protein between hCtBP2 and p53 is analogous to the 
role played by CtIP in recruiting CtBP to BRCA1 [23]. Our model is further supported by recent 
evidence that hdm2 can be recruited to p53-responsive promoters through p53 binding [24]. The 
promoter specificity of this effect in our assays may reflect the known requirement for CtBP 
proteins to be recruited to sites located within a short distance of the promoter for repression to 
occur [17]. Consistent with this known property of CtBP proteins, the p53-responsive promoters 
used in this study which were sensitive to inhibition by hCtBP2 (bax-Luc and hdm2-Luc03) both 
have p53-response elements (p53-RE) situated within 500 b.p. of the transcription start site, 
whereas in the non-responsive p21-promoter, the p53-RE is located further upstream at –2400. It 
is important to consider, however, that the mechanisms whereby CtBP represses transcription 
remain largely undefined, and may be dependent on the context of individual promoters. 
Specifically, CtBP proteins can recruit histone deacetylase proteins, including HDAC1 [25, 26], 
and repression by CtBP can be either depdendent [16] or independent [27] of HDAC activity. 
Hdm2 has recently be shown to recruit HDAC1 to p53 though an undefined bridging protein, 
resulting in de-acetylation of p53 and a reduction in the expression of p53-response genes 
including hdm2 and p21WAF-1 [28]. If CtBP proteins function as this bridging molecule, then they 
could be predicted to have HDAC1-dependent inhibitory effects on promoters such as p21WAF1, 
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in addition to the effects on the hdm2 and bax promoters which were observed in the absence of 
HDAC1 transfection. 
 
Whilst we have clearly demonstrated that a hypoxia-regulated interaction occurs between 
endogenous hdm2 and hCtBP2 proteins, our data defining the functional consequence of this 
interaction is dependent of the analysis of synthetic reporter constructs. However, recent analysis 
of gene expression profiles in mouse embryo fibroblasts (MEFs) from CtBP1 and 2 homozygous 
null animals has recently confirmed that CtBP can repress expression of a range of endogenous 
p53 target genes, including Bax, PERP and Noxa [29]. Expression of all of these genes was up-
regulated in CtBP null MEFs, and re-repressed when CtBP2 was re-expressed in these cells. 
Reporter-based assays performed by the authors of this manuscript lead them to conclude that 
this effect was independent of a direct effect of CtBP on p53, and the mechanism underlying the 
inhibition was not defined. However their assays were performed in the absence of hdm2 co-
transfection, and under conditions of chemotherapeutic drug exposure, which would have 
disrupted the interaction between hdm2 and p53, and therefore would have been unlikely to have 
detected the effects that we have demonstrated here. The authors also clearly demonstrated that 
CtBP null MEFs are hypersensitive to cell killing by a range of pro-apoptotic stimuli, with clear 
implications for the role of CtBP family proteins in tumour biology. Evidence that we have 
presented here provides, in part, a mechanistic explanation for these striking observations.  
 
Hdm2 is emerging as a key regulator of cell-cycle control and commitment to apoptosis [21]. 
The identification of protein:protein interactions made by hdm2 has resulted in a number of 
significant advances in our understanding of how these processes can be controlled by diverse 
cellular stimuli, such as the activation of oncogenes [30] and ionising radiation [4]. Several 
hdm2-binding proteins are also promising targets for the design of novel cancer therapies [31]. 
Hypoxic stress induces a p53-dependent apoptotic response, and in many types of cancer may be 
responsible for the positive growth advantage of tumour cells in which the p53 gene is mutated 
[32]. The mechanisms whereby hypoxia, and hypoxia-mimicking chemicals such as CoCl2 and 
deferoxamine, induce p53-dependent apoptosis are now beginning to be elucidated. There is 
evidence that the mechanism may either be dependent, or independent, on the activation of p53’s 
trans-activation activity, depending on the cell type being studied, and the exact nature of the 
stress involved [5, 33]. Our finding that hypoxia-mimicking conditions result in the dissociation 
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of hdm2:hCtBP2 complexes, and a de-repression of p53-dependent transcription, provides a 
significant advance in the understanding of these pathways.  
 
CtBP family members interact with, and modify the activity of, a large number of proteins with 
key roles in development, differentiation, cell-cycle control and apoptosis [13, 14, 34]. The 
majority of the interactions that have been described to date are dependent on the presence of a 
PXDLS motif in the interacting protein. In a recent two-hybrid analysis [35], however, 13 of 41 
CtBP-interacting clones did not contain this motif, and similarly, there is no PXDLS sequence in 
hdm2. We have demonstrated that the NADH-induced conformational change in CtBP family 
members, which is known to result in an increase in their affinity for PXDLS motif-proteins, 
causes a decrease in hCtBP2 binding to hdm2 protein, and we anticipate the discovery of other 
CtBP-protein interactions which are regulated by NADH in this way. In summary, our data 
demonstrates that NADH-binding by CtBP proteins does not act as a simple ‘on-off switch’ for 
binding to one set of transcription factors, but rather a mechanism to regulate the differential 
recruitment of CtBP by two distinct groups of proteins in the cell. 
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Figure 1 Hdm2 interacts with hCtBP2 in vitro and in vivo. (A) Partially purified recombinant 
hdm2 was incubated with the GST-fusion proteins indicated, and complexes pulled down using 
glutathione-sepharose beads. Samples were then analysed by SDS-PAGE followed by either 
Coomassie blue staining to demonstrate equal amounts of GST-fusion protein, or western 
blotting with mAb 2A10 to detect hdm2. (B) Extracts from MCF-7 cells were 
immunoprecipitated with protein G beads alone (-), an irrelevant goat Ig to caspase 6 (control), 
or E16 goat-polyclonal antibody to CtBP. Precipitates were then analysed by immunoblotting, 
using rabbit polyclonal Ig R41 to hCtBP2, and hdm2 mAb 2A9. (C) Recombinant full length 
GST-hCtBP2(1-445), GST-hCtBP2 deletion mutants, and GST alone, were used as bait in GST 
‘pull-down’ assays with equal amounts of full length hdm2. Coomassie blue staining was used to 
confirm equivalent amounts of the CtBP2 mutants had been used (upper panel) and 
immunoblotting with mAb 2A10 was used to detect co-immunoprecipitated hdm2 (lower panel). 
A comparison between the mutants and the known domains of hCtBP2 is shown, with the N-
terminal GST-fusion omitted. (D) GST-hCtBP2(1-110) was used to pull down the hdm2 deletion 
mutants indicated. Equal amounts of input proteins were confirmed using western blotting with 
mAb 4B2 for hdm2 and Coomassie blue staining for GST-hCtBP2(1-110). Co-
immunoprecipitated hdm2 was detected by immunoblotting with mAb 4B2. The location of the 
hdm2 deletion mutants with reference to known domains of hdm2 are shown: (P)=p53-binding 
domain; (NL/NE)=Nuclear localisation and export sequences; (A)=acidic region; (Z)=Zinc 
finger; (R)=RING finger.  
 
Figure 2 The hdm2:hCtBP2 interaction is inhibited by NADH-binding to the hCtBP2 
dehydrogenase domain. (A) Multiple sequence alignment of the conserved GXGXXG 
NAD+/NADH binding site of hCtBP1, hCtBP2, and the human D-isomer specific 2-Hydroxyacid 
Dehydrogenase enzyme (hD-2HADH). The affinity of the site in hCtBP1 has been reported to be 
approximately 100 fold greater for NADH than NAD+ [15]. The arrow marks the site of the 
alanine substitution mutant in hCtBP2 (G189A). (B) The interaction between hdm2 and the 
indicated GST-hCtBP2 fusion proteins was determined by GST ‘pull-down’ assay in the 
presence of increasing concentrations of NADH. (C) MCF-7 cells were treated for 2 hr with 200 
µM CoCl2 or hypoxia (<1% O2) where indicated. Cell lysates were immunoprecipitated (IP) with 
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goat polyclonal anti-CTBP (E-16), or a control antibody to caspase 6 and immunoprecipitated 
proteins analysed by western blot with antibodies for CtBP (R41) and hdm2 (2A10). 
 
Figure 3 Recruitment of hCtBP2 by hdm2 results in promoter-selective repression of p53-
dependent transcription. (A) HEK 293 cells were transfected with 200 ng of the p53-dependent 
reporter vector containing either p21WAF1, hdm2 or bax promoter sequences, 25 ng of wild-type 
p53 expression vector, and 200 ng of hdm2 expression vector to give conditions where 
approximately 70% inhibition of p53 activity by the co-transfected hdm2 was achieved. 
Transfections also included 1 µg of either pcDNA 3.1 (solid bars) or pcDNA3mychis hCTBP2 
(open bars) expression vectors. Relative luciferase activity (RLA) was first calculated by 
normalisation to expression from a co-transfected β-galactosidase expression vector, and the 
RLA of each promoter in the presence of pcDNA3.1 was defined as 100%.  In the absence of 
p53, promoter activity was approximately 2%. (B) HEK 293 cells were transfected with the 
hdm2-Luc03 p53-responsive reporter vector (which contains only 165 b.p. of hdm2 promoter 
sequence including the two p53 response elements) and the indicated amounts of expression 
vector. 30 hr post-transfection, cells were treated for 16 hr with 200 µM CoCl2 before assaying. 
(C) Transfections were repeated as in (B), with the addition of the NADH-insensitive G189A 
mutant of hCtBP2. (D) Hdm2-Luc03 reporter assays in HEK 293 cells were performed using the 
indicated vectors. hCtBP2(G189A) was used in this experiment as it functions as a 
constitutively-active mutant which is insensitive to variations in intracellular NADH.  
 
Figure 4 Proposed model of the mechanism whereby hdm2 recruits CtBP proteins to negatively 
regulate p53-dependent transcription. (A) Recombinant human p53, hdm2, and GST-hCtBP2(1-
110) were mixed as indicated and subjected to either GST ‘pull-down’ analysis or 
immunoprecipitation with mAb 2A9 to hdm2. Co-precipitated p53 was detected with polyclonal 
antibody CM1. (B) Model for the promoter-selective inhibition of p53-dependent transcription 
by CtBP proteins. Given the high degree of functional homology between hCtBP1 and hCtBP2, 
and the ability of the two proteins to form hetero-dimers, it is probable that hCtBP1 is also able 
to repress p53 activity by this mechanism. 
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SUPPLEMENTARY MATERIAL 
 
MATERIALS AND METHODS 
 
Library screen 
A HeLa cell cDNA Uni-ZAP XR protein expression library (Stratagene) was screened according 
to the manufacturers instructions. Plaques were lifted onto nitrocellulose filters, blocked with 1% 
bovine serum albumin (BSA) in 0.05% T-TBS (0.05% Tween-20 in Tris-buffered saline) and 
probed with pre-formed complexes of recombinant E. coli-expresssed hdm2 (100 ng/ml) and 
mAb 4B2 (0.5 ng/ml) in 3% BSA, 1% bacterial cell lysate (Stratagene), 1 mM Benzamidine, 5 
mM DTT, 0.05% T-TBS. Following extensive washing in 0.1%T-TBS, bound complexes were 
detected with alkaline phosphatase-conjugated rabbit anti-mouse antibody, followed by washing 
and detection by BCIP-NBT reagent (Stratagene). Positive plaques were subjected to further 
screening, before excision of the pbluescipt (pBSK) phagemid containing the cDNA. 
 
Expression vectors, proteins, and antibodies 
 The full length GST-hCtBP2 expression vector and the panel of GST-hCtBP2 deletion constructs 
were cloned into the pGEX-2TK expression vector (Amersham Biosciences) by proof reading-
PCR amplification of the pBSK-hCtBP2 plasmid which had been derived from the cDNA library 
screen. Full length hCtBP2 was also cloned into the pcDNA3-mychisA vector (Invitrogen) using 
BamHI and KpnI restriction sites. A G189A mutation was introduced into hCtBP2 using side-
directed mutagenesis (Quickchange, Stratagene). pT7.7hdm2(6-491) and pCMVhdm2(1-491) 
vectors were used to generate hdm2 truncation mutants deletions by the insertion of TGA stop 
codons. Expression of soluble protein in E.coli from pT7.7hdm2, pT7.7hdmX, pGEX-2TK-
hCtBP2 and pGEX-4T1-hCtBP1 vectors was performed using established procedures. Human 
p53 was expressed in Sf9 cells and partially purified using heparin-sepharose chromatography. 
P21-Luc and bax-Luc reporter vectors have been described previously, hdm2-Luc03 contains 
165 b.p. of the hdm2 P2 promoter including the two p53-response elements. R41 antibody to 
recombinant hCtBP2, and anti-hdmX were generated by Moravian Technologies.  
 
Tissue culture, transfection and reporter assays 
Human HEK 293 and MCF-7 cells were cultured in Dulbecco’s modified Eagle’s medium 
supplemented with 10% foetal calf serum. Hypoxia (<1% O2) was generated using an Anaerogen 
  
    
hypoxic chamber system (Oxoid, U.K.). Transient transfections were conducted using the 
TransFastTM transfection reagent (Promega). For each transfection, the total amount of DNA 
used was kept constant by adding the relevant empty vector. pcDNA3mychis-LacZ (β-
galactosidase) was included in all reporter assay transfections to allow normalisation for 
transfection efficiency. For reporter assays, cells were harvested 48 hours after transfection and 
lysed in reporter lysis buffer (0.65% IGEPAL CA-630, 10 mM Tris-HCl pH 8.0, 1 mM EDTA, 1 
mM NaCl) for 2 min at room temperature before centrifuging at 13,000 g for 3 min. Supernatants 
were assayed for Luciferase activity using LucLite reagent (Packard), and a TopCount 
microplate luminometer (Packard). Luciferase activity was normalised to β-galactosidase activity 
in all experiments. Assays were performed in duplicate, and representative data from repeat 
experiments is shown.  
 
Protein analysis 
For in vitro binding assays, GST fusion proteins were incubated overnight at 4 ˚C with 10-20 µl 
of glutathione-sepharose beads slurry (Amersham Pharmacia) and subsequently washed 3-5 
times with ice-cold NETS buffer (50 mM Tris.HCl pH 7.6, 150 mM NaCl, 5 mM EDTA, 1% 
IGEPAL CA-630, 5mM DTT), to remove unbound proteins. Samples were incubated for 1 hr 
with recombinant hdm2 at room temperature, before washing again. Precipitated proteins were 
eluted by boiling in SDS sample buffer and resolved by SDS-PAGE for western blotting. For 
immunoprecipitation from whole cell lysates, cells were rinsed in ice-cold PBS, scraped, and 
pelleted. Lysis was conducted with 1-2 volumes of NETS buffer containing CompleteTM protease 
inhibitor (Boehringer Ingelheim) for 15 minutes on ice before centrifuging the sample at 13,000g 
for 10 min. Supernatants were then pre-cleared using a small volume of protein G-sepharose 
beads, and immunoprecipitated overnight at 4˚ C with either the mAb 9E10 to the myc tag, or the 
polyclonal goat antibodies E16 (CtBP1&2, Santa Cruz) and K-20 (caspase 6, Santa Cruz). 
Precipitated proteins were then recovered by incubating the mixture with protein G-sepharose 
beads for 1 hr at room temperature, fractionated by 10% SDS-PAGE, and transferred onto 
nitrocellulose. Proteins were detected using the mAb 2A9 and 2A10 (hdm2), 3G10 (GST, 
Abcam), and polyclonal antibodies E16 and R41 (hCtBP2). For farwestern analysis, bacterial 
lysate containing either recombinant GST-hCtBP2 or GST (in 5% milk, 0.1% Tween-20, PBS) 




    
FIGURE LEGENDS 
 
Figure S1 Hdm2 and hCtBP2 interact in vitro and in vivo (A) Farwestern analysis of the 
hdm2:hCtBP2 interaction. IPTG-induced cell lysates from E.coli BL21 (DE3) cells that had been 
transformed with either no plasmid (control), pT7.7hdm2, or pT7.7p53 were subjected to SDS-
PAGE and transferred to nitrocellulose membranes. Identical membranes were either probed 
directly for hdm2 using mAb 2A9, or subjected to farwestern analysis using either GST-hCtBP2 
or GST protein as a probe, and anti-GST antibody for detection. Gels were stained with 
Coomassie blue to confirm that equal amounts of bacterial lysate were loaded. (B) HEK 293 
cells were transfected with pCMVhdm2 and either pcDNA3mychis-LacZ (β-galactosidase) or 
pcDNA3mychis-hCTBP2 expression vectors. 40 hr later, cells were treated with 20 µM MG132 
(to prevent proteasomal degradation of hdm2) for 2 hr before cell lysis. Immunoprecipitation (IP) 
was performed with mAb 9E10 to myc, and co-immunoprecipitated hdm2 detected by mAb 
2A10. Comparable levels of both hdm2 (lanes 1 and 2), and the myc-tagged transfected proteins 
(not shown)  in the input cell-lysates were also confirmed  
 
Figure S2 Interaction between hdm2 and hCtBP2 paralogues. (A) HdmX was subjected to GST 
‘pull-down’ analysis using GST-hCtBP2 or GST alone as bait. Detection was with polyclonal 
antisera to hdmX. (B) Hdm2 was subjected to GST ‘pull-down’ analysis using either GST alone, 
GST-hCtBP2 or GST-hCtBP1 as indicated 
 
Figure S3 Hdm2 does not target hCtBP2 for degradation. HEK 293 cells were  transfected with 
increasing amounts of hdm2 and equal amounts of myc-hCtBP2 and myc-β-galactosidase 
expression vectors as indicated. 40 hr later, cell extracts were prepared, and western blotted 
using mAb 9E10 for myc-epitope detection, and mAb 2A10 for hdm2.  
 
  
    
  
Fig S1 
 
 
 
Fig S2 
 
 
 
 
Fig S3 
 
